The BCL11A Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the HeLa human cervical adenocarcinoma cell line, offering a heterogeneous loss-of-function model for studying BCL11A gene disruption. This polyclonal format preserves genetic diversity while ensuring consistent target gene knockout across large-scale cultures, suitable for various cell-based assays.
The parental HeLa cell line is an HPV18-positive cervical adenocarcinoma epithelial cell line established in 1951 from Henrietta Lacks. Its immortalized nature and robust proliferation make it a well-established platform in cancer research and molecular biology, providing an epithelial context to explore transcription factor functions beyond hematopoietic lineages.
BCL11A is a zinc finger transcription factor that serves as a critical repressor of fetal hemoglobin by binding to the gamma-globin (HBG1/HBG2) promoters and recruiting the NuRD chromatin remodeling complex, which includes CHD4, HDAC1/2, and MTA2, to deacetylate histones and silence transcription. Upstream regulators such as KLF1, GATA1, and EBF1 control BCL11A expression, while its transcriptional repression activity is mediated through interactions with GATA1, SOX6, FOG1 (ZFPM1), and NR2F2. Beyond globin switching, BCL11A regulates key genes involved in cell cycle and proliferation, including CCND2, MYC, and BCL6, underscoring its roles in B-cell development and lymphomagenesis.
In the HeLa cervical carcinoma background, the BCL11A polyclonal knockout enables dissection of fundamental transcriptional repression mechanisms and chromatin remodeling processes independent of erythroid or lymphoid lineage factors. Researchers can assess the functional consequences of BCL11A loss on cell proliferation, apoptosis, and migration, as well as examine its interaction with the NuRD complex within an epithelial cancer model.
Representative applications include chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) to evaluate NuRD complex occupancy at BCL11A target loci, gene expression profiling by RNA-seq or RT-qPCR for target validation, and a suite of functional assays measuring proliferation, apoptosis, and migration/invasion. Protein-level analysis by Western blot, immunofluorescence, and flow cytometry verifies knockout efficiency. This product is suitable for drug target validation and research into BCL11A-related disorders such as sickle cell disease, beta-thalassemia, and B-cell malignancies. For additional information or custom product inquiries, please contact Ascent Research.
